Nearly all postmenopausal women with early-stage HR+ breast cancer are treated with aromatase inhibitors. But these drugs can significantly compromise bone health and up the risk of fractures.

Denosumab – sold under the brand names of Prolia for the treatment of osteoporosis and Xgeva for fracture prevention in patients with metastatic cancers to the bone – may be effective in treating people with a condition known as giant-cell tumor of the bone.

When breast cancer spreads to the bones, various drugs are available to control the disease. This class of drugs is called biophosphonates . A manufacturer-funded study suggests its drug is better than others.